Your browser doesn't support javascript.
loading
Current strategic thinking for the development of a trivalent alphavirus vaccine for human use.
Wolfe, Daniel N; Heppner, D Gray; Gardner, Shea N; Jaing, Crystal; Dupuy, Lesley C; Schmaljohn, Connie S; Carlton, Kevin.
Afiliación
  • Wolfe DN; Chemical and Biological Technologies Department, Defense Threat Reduction Agency, Fort Belvoir, Virginia; TASC, Inc., Lorton, Virginia; Computations/Global Security, Lawrence Livermore National Laboratory, Livermore, California; Physical and Life Sciences Directorate, Lawrence Livermore National Lab
  • Heppner DG; Chemical and Biological Technologies Department, Defense Threat Reduction Agency, Fort Belvoir, Virginia; TASC, Inc., Lorton, Virginia; Computations/Global Security, Lawrence Livermore National Laboratory, Livermore, California; Physical and Life Sciences Directorate, Lawrence Livermore National Lab
  • Gardner SN; Chemical and Biological Technologies Department, Defense Threat Reduction Agency, Fort Belvoir, Virginia; TASC, Inc., Lorton, Virginia; Computations/Global Security, Lawrence Livermore National Laboratory, Livermore, California; Physical and Life Sciences Directorate, Lawrence Livermore National Lab
  • Jaing C; Chemical and Biological Technologies Department, Defense Threat Reduction Agency, Fort Belvoir, Virginia; TASC, Inc., Lorton, Virginia; Computations/Global Security, Lawrence Livermore National Laboratory, Livermore, California; Physical and Life Sciences Directorate, Lawrence Livermore National Lab
  • Dupuy LC; Chemical and Biological Technologies Department, Defense Threat Reduction Agency, Fort Belvoir, Virginia; TASC, Inc., Lorton, Virginia; Computations/Global Security, Lawrence Livermore National Laboratory, Livermore, California; Physical and Life Sciences Directorate, Lawrence Livermore National Lab
  • Schmaljohn CS; Chemical and Biological Technologies Department, Defense Threat Reduction Agency, Fort Belvoir, Virginia; TASC, Inc., Lorton, Virginia; Computations/Global Security, Lawrence Livermore National Laboratory, Livermore, California; Physical and Life Sciences Directorate, Lawrence Livermore National Lab
  • Carlton K; Chemical and Biological Technologies Department, Defense Threat Reduction Agency, Fort Belvoir, Virginia; TASC, Inc., Lorton, Virginia; Computations/Global Security, Lawrence Livermore National Laboratory, Livermore, California; Physical and Life Sciences Directorate, Lawrence Livermore National Lab
Am J Trop Med Hyg ; 91(3): 442-50, 2014 Sep.
Article en En | MEDLINE | ID: mdl-24842880
Vaccinations against the encephalitic alphaviruses (western, eastern, and Venezuelan equine encephalitis virus) are of significant interest to biological defense, public health, and agricultural communities alike. Although vaccines licensed for veterinary applications are used in the Western Hemisphere and attenuated or inactivated viruses have been used under Investigational New Drug status to protect at-risk personnel, there are currently no licensed vaccines for use in humans. Here, we will discuss the need for a trivalent vaccine that can protect humans against all three viruses, recent progress to such a vaccine, and a strategy to continue development to Food and Drug Administration licensure.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Virales / Infecciones por Alphavirus / Alphavirus / Encefalitis Viral Límite: Animals / Humans Idioma: En Revista: Am J Trop Med Hyg Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Virales / Infecciones por Alphavirus / Alphavirus / Encefalitis Viral Límite: Animals / Humans Idioma: En Revista: Am J Trop Med Hyg Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos